Oruka Therapeutics leads with ORKA-001, a promising ultra-long-acting psoriasis treatment showing strong trial results.

Oruka Therapeutics is advancing as a leader in ultra-long-acting injectable treatments for psoriasis with its drug ORKA-001, which demonstrates high efficacy in clinical trials. The drug shows strong PASI 100 and PASI 90 response rates at Week 28, indicating durable effects, and consistent results were seen in a crossover cohort. With $1.1 billion in cash and exclusive rights to Hypercon technology, Oruka is well-funded to support ongoing research and development, including upcoming Phase 3 trials and key data releases. ORKA-001 has the potential to generate multibillion-dollar revenue, positioning the company strategically in the psoriasis treatment market.

As of Oct 18, 2026 17:51 WIB, Oruka Therapeutics Inc. (ORKA) is trading at USD 71.93 on Pluang, down 2.63% for the day. The company holds a market capitalization of $4.77 billion and an enterprise value of $3.90 billion. This valuation underscores the significant investor interest in Oruka's innovative psoriasis treatment developments.